ASH 2019 – CLL

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53

ASH 2019 – CLL

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia

ASH 2019 – CLL

Page 4 of 4

1
2
3
4

Conference Coverage Proudly Presented by

CONQUER: the patient voice

Learn more about our family of publications.

View Our Publications